Recruiting

Serratus Anterior Plane Block

Sponsor:

Wayne State University

Code:

NCT05090761

Conditions

Post Operative Pain, Acute

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bupivacaine 0.25% Injectable Solution

Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg

Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg

Study Details

Brief summary:

The purpose of this study is to determine whether the addition of the serratus anterior plane block (SAPB) alone (30 mL of 0.25% bupivacaine) or plus Magnesium (150 mg of magnesium sulfate) or plus Magnesium + Buprenorphine (300 mcg) as adjuvants can improve post-operative pain in patients undergoing video-assisted thoracoscopic surgery.

Conditions

Post Operative Pain, Acute

Study ID

NCT05090761

Start date

Oct 12, 2021

Status verified date

Oct, 2021

Completion date

Oct, 2022

Anticipated

Primary completion date

Oct, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

- Patients undergoing video-assisted thoracoscopy

Exclusion Criteria:

  • Patients with significant genetic or acquired clotting/bleeding disorders (hemophilia, DIC, etc.)
  • Patients with significant platelet dysfunction
  • Infection at site for regional anesthesia
  • Allergy to local anesthetics
  • Sepsis

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

active comparator: SAPB

40 Patients - Patients will receive 30 mL of 0.25% bupivacaine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.

active comparator: SAPB with Mg

40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.

active comparator: SAPB with Mg and Buprenorphine

40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg and 300 mcg of buprenorphine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.

Interventions

Bupivacaine 0.25% Injectable Solution

Injection of Bupivacaine 0.25% Injectable Solution for SAPB

Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg

Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant

Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg

Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants

Primary outcome measure

  • Post-operative total opioid consumption (oral morphine equivalents) [ Time Frame: 24 hours after surgery ]
  • Visual analog scale (VAS) pain scores [ Time Frame: 6 hours after surgery ]
  • Visual analog scale (VAS) pain scores [ Time Frame: 12 hours after surgery ]
  • Visual analog scale (VAS) pain scores [ Time Frame: 24 hours after surgery ]

Central Contacts and Locations

Central contacts

Sandeep Krishnan, M.D.

(248) 858-6068sakrishna@med.wayne.edu

Locations

St. Joseph Mercy Oakland Hospital

Recruiting

Pontiac, Michigan, United States, 48341

Contacts

Lena Anderson

248-858-6068

More Information

Sponsor

Wayne State University

Last update posted

Oct 25, 2021

Last verified

Oct, 2021

Keywords

  • Serratus anterior plane block, video-assisted thoracoscopy, opioid consumption, magnesium, buprenorphine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Wayne State University on 2021-10-25.